par Bouwhuis, Marna G;Suciu, Stefan 
;Collette, Sandra;Aamdal, S;Kruit, Wim H;Bastholt, Lars;Stierner, Ulrika;Sales, François ;Patel, Poulam;Punt, Cornelis;Hernberg, Micaela;Spatz, Alain;ten Hagen, Timo L M;Hansson, Johan;Eggermont, A;EORTC Melanoma Group and the Nordic Melanoma Group,
Référence Journal of the National Cancer Institute, 101, 12, page (869-877)
Publication Publié, 2009-06
;Collette, Sandra;Aamdal, S;Kruit, Wim H;Bastholt, Lars;Stierner, Ulrika;Sales, François ;Patel, Poulam;Punt, Cornelis;Hernberg, Micaela;Spatz, Alain;ten Hagen, Timo L M;Hansson, Johan;Eggermont, A;EORTC Melanoma Group and the Nordic Melanoma Group, Référence Journal of the National Cancer Institute, 101, 12, page (869-877)
Publication Publié, 2009-06
Article révisé par les pairs
| Résumé : | Appearance of autoantibodies and clinical manifestations of autoimmunity in melanoma patients treated with adjuvant interferon (IFN)-alpha2b was reported to be associated with improved prognosis. We assessed the association of the appearance of autoantibodies after initiation of treatment with recurrence-free interval in two randomized trials that compared intermediate doses of IFN with observation for the treatment of melanoma patients. |
